At this time, posts about Ollipass are rapidly increasing on portals and stock communities. Today, foreigners have sold a net 3,000 shares of Ollipass, and institutions have sold a net 143,000 shares, according to preliminary estimates.


As of 1:30 PM on the 9th, Ollipass's stock price is 15,050 KRW, down 29.18% from the previous day, with a trading volume of 5,266,736 shares, which is 2009.23% of the 5-day average trading volume. On March 8, Ollipass was a market issue with the headline "Painkiller new drug OLP-1002 Australia clinical trial... unusual event, lower limit price."


In addition to Ollipass, posts by investors are also surging for ATEKTN (224110), Mobeis Electronics (012860), and Samsung SDI (006400).


Hot Picks Today

"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ① "Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①

※ Source: AI Investment Assistant AI Lassiro


※ This article was generated in real time by an article automatic generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.


한글 기사 보기
This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing